A review article discusses how KRAS G12C mutations account for 3% to 4% of metastatic colorectal cancer cases and explains why combined KRAS G12C and EGFR inhibition may be more effective than monotherapy. (Journal of Gastrointestinal Cancer)
KRAS G12C Inhibitors in Metastatic CRC: Combination Strategies Reviewed
The CRC Digest